Pharma IQ revisits the compound and biobanking markets to pinpoint any shifts or new trends in the market.
We spoke to CRISPR experts Robin Ketteler and Lorena Benedetti to find out about their work within CRISPR, insights on where the technique is heading and the field’s exciting developments.
Unsurprisingly, it can be a challenge for the industry to keep pace with all of these entities and the best practices that they are putting forward. In response to this, Pharma IQ has created this snapshot guide to a election of bodies active within the single-use-systems market to provide insight into their achievements over the past year and... Read more
The melanoma pipeline, which is typically underserved due to stubborn R... Read more
With several patent expiries in 2015 and 2016, there was high expectation that a significant portion of the biologics market would shift to biosimilar use by 2016, especially in the areas of diabetes, rheumatology, and in tendering markets. I
Single use systems in biomanufacturing can greatly simplify the path to market. This is due to the reduction of sterilisation time and spend, lowered labor efforts, swifter set up times, lower cross contamination levels and reduced operating costs in the production of pharma products. As a result, many are implementing more single use systems... Read more
The last quarter of 2016 was certainly not short of activity with a £84 million pharma fine issued in regards to drug pricings, an investigation into a suspected supply chain breach and numerous therapeutic approvals.
Looking ahead, the United States is expected to retain its dominant position within the toxicology testing market, although as with many areas of the pharmaceutical industry, the greatest levels of growth are expected to be seen in Asia Pacific.